From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F18%3AA1901VZ5" target="_blank" >RIV/61988987:17110/18:A1901VZ5 - isvavai.cz</a>

Alternative codes found

RIV/00843989:_____/18:E0107032

Result on the web

<a href="http://dx.doi.org/10.3324/haematol.2017.174573" target="_blank" >http://dx.doi.org/10.3324/haematol.2017.174573</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3324/haematol.2017.174573" target="_blank" >10.3324/haematol.2017.174573</a>

Result language

angličtina

Original language name

From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives

Original language description

Survival of myeloma patients has greatly improved with the use of autologous stem cell transplantation and novel agents, such as proteasome inhibitors, immunomodulatory drugs and monoclonal antibodies. Compared to bortezomib- and lenalidomide-based regimens alone, the addition of high-dose melphalan followed by autologous transplantation significantly improves progression-free survival, although an overall survival benefit was not observed in all trials. Moreover, follow up of recent trials is still too short to show any difference in survival. In the light of these findings, novel agent-based induction followed by autologous transplantation is considered the standard upfront treatment for eligible patients (level of evidence: 1A). Post-transplant consolidation and maintenance treatment can further improve patient outcome (1A). The availability of several novel agents has led to the development of multiple combination regimens such as salvage treatment options. In this context, the role of salvage autologous transplantation and allotransplant has not been extensively evaluated. In the case of prolonged remission after upfront autologous transplantation, another autologous transplantation at relapse can be considered (2B). Patients who experience early relapse and/or have high-risk features have a poor prognosis and may be considered as candidates for clinical trials that, in young and fit patients, may also include an allograft in combination with novel agents (2B). Ongoing studies are evaluating the role of novel cellular therapies, such as inclusion of antibody-based triplets and quadruplets, and chimeric antigen receptor-T cells. Despite encouraging preliminary results, longer follow up and larger patient numbers are needed before the clinical use of these novel therapies can be widely recommended.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30205 - Hematology

Project

—

Continuities

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Publication year

2018

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

HAEMATOLOGICA

ISSN

0390-6078

e-ISSN

—

Volume of the periodical

103

Issue of the periodical within the volume

2

Country of publishing house

IT - ITALY

Number of pages

15

Pages from-to

197-211

UT code for WoS article

000423853800016

EID of the result in the Scopus database

2-s2.0-85041539082